Q3 2018 13F Holders as of 9/30/2018
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
86M
-
Number of holders
-
168
-
Total 13F shares, excl. options
-
22.8M
-
Shares change
-
+4.34M
-
Total reported value, excl. options
-
$1.01B
-
Value change
-
+$171M
-
Put/Call ratio
-
2.54
-
Number of buys
-
87
-
Number of sells
-
-76
-
Price
-
$44.35
Significant Holders of CRISPR Therapeutics AG - Common Stock (CRSP) as of Q3 2018
232 filings reported holding CRSP - CRISPR Therapeutics AG - Common Stock as of Q3 2018.
CRISPR Therapeutics AG - Common Stock (CRSP) has 168 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 22.8M shares
of 86M outstanding shares and own 26.57% of the company stock.
Largest 10 shareholders include Versant Venture Management, LLC (3.61M shares), NEA Management Company, LLC (2.09M shares), ARK Investment Management LLC (1.45M shares), Abingworth LLP (1.24M shares), FARALLON CAPITAL MANAGEMENT LLC (1.02M shares), WADDELL & REED FINANCIAL INC (1M shares), WELLINGTON MANAGEMENT GROUP LLP (772K shares), FEDERATED INVESTORS INC /PA/ (764K shares), BlackRock Inc. (710K shares), and CREDIT SUISSE AG/ (596K shares).
This table shows the top 168 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.